Skip to main content
. Author manuscript; available in PMC: 2019 Sep 30.
Published in final edited form as: Adv Exp Med Biol. 2018;1065:433–454. doi: 10.1007/978-3-319-77932-4_27

Table 27.2.

Progestins in oral contraceptives ranked according to risk for venous thrombosisa

Oral contraceptive Risk of
thrombosis
First-generation <50 μg ethinyl estradiol with the progestins norctynodrel, norethisterone. and norcthisterone acetate 6–12/10,000 women
Third-generation <50 μg ethinyl estradiol with the progestins desogcstrel or gestodene or norgestimate 9–12/10.000 women
Fourth-generation <50 μg ethinyl estradiol with the progestins drospirenone. dienogest. or nomegcstrol acetate 9–12/10.000 similar
Second-generation <50 μg ethinyl estradiol with the progestins norgestrel or levonorgestrel 5–7/10.000 women
Progestin-only (norcthisterone. ethynodiol diacetate. levonorgestrel. desogestrel. lynestrenol) 2–3/10.000 women
a

Derived from Table 27.1 of (iialcraki ct al. [116] reprinted with permission